Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 9/20 | 0.59 |
| ▸ | CDK2 | P24941 | 8/20 | 0.59 |
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.41 |
| ▸ | TTBK1 | Q5TCY1 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16610272 | 0.80 | CDC7 (0.71) | CDC7CDK2MAP3K14ROCK1TTBK1 | |
| SCHEMBL16610304 | 0.76 | TTBK1 (0.74) | CDC7CDK2MAP3K14TTBK1TTBK2 | |
| SCHEMBL3301546 | 0.75 | CDC7 (0.57) | CDC7CDK2MAP3K14ROCK1MAPT | |
| SCHEMBL27985116 | 0.71 | CDK2 (0.53) | CDC7CDK2ROCK1MKNK1MKNK2 | |
| SCHEMBL3304129 | 0.70 | CDC7 (0.56) | CDC7CDK2ROCK1MKNK1MKNK2 | |
| SCHEMBL20476705 | 0.67 | PIK3CB (0.49) | MAPT | |
| SCHEMBL1614212 | 0.66 | CDK2 (0.60) | CDC7CDK2MAP3K14ROCK1MAPT | |
| SCHEMBL19100724 | 0.66 | CDC7 (0.56) | CDC7CDK2MAP3K14ROCK1TTBK1 | |
| SCHEMBL19379725 | 0.66 | — | — | |
| SCHEMBL24152672 | 0.64 | CDC7 (0.57) | CDC7CDK2MAP3K14ROCK1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071566-B1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-15 | — | — | EP | disclosed |
| US-10005773-B2 | 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-10005773-B2 | 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-20160257679-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2016-09-08 | — | — | US | disclosed |
| US-20160257679-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2016-09-08 | — | — | US | disclosed |
| WO-2015044267-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005773-B2 | 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors | MAP3K14, MAP3K15, MAP3K12 | CDC7 620/4885CDK2 784/4885MAP3K14 1/4885 |
| US-20160257679-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K12 | CDC7 548/4885CDK2 673/4885MAP3K14 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.